You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

380 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - For relapsed and refractory Mantle Cell Lymphoma, according to clinical criteria
Jun 2025
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Neoadjuvant
Jun 2017
Regimen
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    leuprolide - long-acting formulation
ODB - General Benefit
    leuprolide - long-acting formulation
May 2025
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Metastatic Breast Cancer
Sep 2025
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Jul 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell, 
Small Cell
Intent: Palliative
Jun 2017
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Jun 2017
Regimen
Cancer Type:
Skin, 
Squamous Cell
Intent: Palliative
Jun 2017
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - For patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to specific criteria.
Jun 2025
Regimen
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
Jun 2017
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
ODB - General Benefit
    letrozole
Aug 2025

Pages